Zależność pomiędzy objętością gruczołu tarczowego a stężeniem przeciwciał przeciwtarczycowych w chorobie Gravesa&#8211;Basedowa po terapii radiojodem by EP redaction,
10
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 63; Numer/Number 1/2012
ISSN 0423–104X
Prof. Jerzy Sowiński MD, Department of Endocrinology, Metabolism and Internal Medicine, University of Medical Sciences,  
ul. Przybyszewskiego 49, 60–355 Poznań, Poland, tel: +48 61 869 13 30, fax: +48 61 869 16 82, e-mail: jsowin@ump.edu.pl?
Correlation between thyroid volume and humoral thyroid 
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przeciwtarczycowych w chorobie Gravesa–Basedowa po terapii radiojodem
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Abstract
Background: Graves’ disease is an autoimmune disorder with the presence of TSH receptor autoantibodies (TRAb). TRAb are produced 
mainly by lymphocytes infiltrating the thyroid gland. The aim of this study was to investigate the influence of the reduction of thyroid 
volume (TV) on TRAb level after radioiodine (RAI) administration in a group of patients with Graves’ disease.
Material and methods: A retrospective chart review of 36 patients with Graves’ disease (age range 18–67 yrs; Me 46 yrs; mean age ± SD 
43 yrs ± 13.0 yrs) treated with RAI administration (the mean dose of RAI ± SD was 46.1 mCi ± 21.7 mCi ) was performed. Data concerning 
TV, TRAb, TSH, and fT4 was collected immediately before administration of radioiodine and 18–36 months thereafter. Data was collected 
before the first administration of RAI and 18–36 months after the last administration of RAI for patients treated with repeated doses of RAI.
Results: Before treatment, mean male (n = 4) TV was 27.9 ml ± 9.6 ml and mean female (n = 32) TV was 20.6 ml ± 12.7 ml. Mean TV was 2.4 ml ± 1.7 ml 
(males) and 5.3 ml ± 10.9 ml (females) after therapy. There was an extremely significant difference between mean TV before RAI administration 
and after 18–36 months. There was an extremely significant difference between the mean serum level of TRAb before and 18–36 months after RAI 
therapy. No significant correlation between percentage reduction of TV and percentage reduction of serum level of TRAb was found.
Conclusions: 1. Decrease of thyroid gland volume after radioiodine therapy is followed by a significant decrease of the level of TRAb after 
18–36 months. 2. TRAb concentration is positively correlated with thyroid gland volume. 3. Percentage reduction of TRAb is not correlated 
with percentage reduction of thyroid volume. (Pol J Endocrinol 2012; 63 (1): 10–13)
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Streszczenie
Wstęp: Choroba Gravesa–Basedowa jest autoimmunologicznym zaburzeniem z obecnością przeciwciał przeciwko receptorowi 
dla TSH (TRAb, TSH receptor autoantibodies). TRAb są wytwarzane głównie przez limfocyty naciekające gruczoł tarczycowy. Celem 
pracy było zbadanie wpływu redukcji objętości tarczycy po terapii jodem radioaktywnym na stężenie TRAb w grupie pacjentów 
z chorobą Gravesa i Basedowa.
Materiał i metody: Przeprowadzono retrospektywną analizę dokumentacji medycznej 36 pacjentów z chorobą Gravesa–Basedowa 
(przedział wieku 18–67 lat; Me 46 lat, śr. wiek ± SD 43 lata ± 13,0 lat) leczonych jodem radioaktywnym (RAI, radioiodine) (śr. dawka I131 ± SD 
46,1 mCi ± 21,7 mCi). Dane dotyczące objętości tarczycy (TV, thyroid volume), TRAb, TSH, fT4 zostały zebrane przed podaniem jodu ra-
dioaktywnego oraz 18–36 miesięcy po podaniu. W przypadku pacjentów leczonych powtórnymi dawkami RAI dane zostały zebrane tuż 
przed podaniem pierwszej dawki oraz 18–36 miesięcy po podaniu dawki ostatniej.
Wyniki: Przed podaniem RAI średnia objętość tarczycy wśród mężczyzn (n = 4) wynosiła 27,9 ml ± 9,6 ml, a wśród kobiet (n = 32) 
20,6 ml ± 12,7 ml. Średnie objętości tarczycy 18–36 miesięcy po terapii wynosiły odpowiednio wśród mężczyzn i kobiet 2,4 ml ± 1,7 ml oraz 
5,3 ml ± 10,9 ml. Stwierdza się istotną statystycznie różnicę między początkową objętością tarczycy oraz objętością gruczołu 18–36 miesięcy 
po leczeniu jodem radioaktywnym. Znajduje się istotną statystycznie różnicę między początkowym stężeniem TRAb oraz stężeniem 
TRAb 18–36 miesięcy po leczeniu radiojodem. Nie stwierdza się istotnej statystycznie korelacji pomiędzy procentową redukcją objętości 
tarczycy oraz procentową redukcją stężenia przeciwciał przeciwko receptorowi dla TSH.
Wnioski: 1. Istotne statystycznie zmniejszenie stężenia TRAb następuje po redukcji objętości tarczycy w wyniku terapii jodem radioaktyw-
nym. 2. Stężenie TRAb wykazuje związek z objętością gruczołu tarczycowego. 3. Procentowa redukcja stężenia TRAb nie jest skorelowana 
z procentową redukcją objętości tarczycy. (Endokrynol Pol 2012; 63 (1): 10–13)
Słowa kluczowe: choroba Gravesa–Basedowa, nadczynność tarczycy, przeciwciała przeciwko receptorowi TSH, 
izotopy jodu promieniotwórczego
Introduction
TSH receptor autoantibodies are used to diagnose 
Graves’ disease (GD), to differentiate GD from other 
variants of autoimmune hyperthyroidism, and to moni-
tor therapeutic effects (after antithyroid drug treatment, 
thyroidectomy or radioiodine). TRAb predict relapse 
of hyperthyroidism in GD [1]. TRAb play a role in the 
pathogenesis of Graves’ orbitopathy (GO) [2], and the 
frequency of GO increases with high TRAb serum level 
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[3]. TRAb serum level is correlated with the severity and 
activity of GO [4, 5].
TSHR antibodies are produced mainly by lymphocytes 
infiltrating the thyroid gland [6]. Extrathyroidal circulat-
ing lymphocytes may also contribute to the production 
of autoantibodies [7]. TRAb serum level usually falls after 
antithyroid drug therapy and thyroidectomy [7]. Necrosis, 
atrophy and fibrosis of follicular cells are biological effects 
of radioiodine therapy. The pattern of TRAb decrease 
during radioiodine treatment has been observed to be 
different than that after surgery or the administration of 
anti-thyroid drugs [8]. Thyroid ablation is suspected to 
eliminate TRAb, possibly due to the removal of most TSH 
receptors or many sensitised T lymphocytes. 
If the thyroid gland is the main source of autoan-
tigens and lymphocytes producing autoantibodies, it 
may be suspected that the decrease of thyroid volume 
is followed by a decrease in the level of TRAb. 
Investigations concerning the course of TRAb titre in 
groups of patients after total thyroidectomy and bilateral 
subtotal resection indicate that if more thyroid tissue is left, 
the risk of recurrent goitre and an unfavourable course of 
TRAb titre is higher [9, 10]. On the other hand, a prospec-
tive randomised study has shown that there is no differ-
ence in TRAb titre between groups of patients after total 
thyroidectomy and subtotal thyroidectomy (less than 4 ml 
of tissue left) [11]. However, thyroid tissue contribution 
in the production of autoantibodies is strongly suggested 
due to the statistically significant decrease of TRAb titre 
after thyroidectomy. 
Aim of the study
The aim of this study was to analyse:
 —  if there was any difference between the serum level 
of TSH receptor autoantibodies (TRAb) before radio-
iodine treatment and after,
 —  if there was a positive correlation between a decrease 
of thyroid volume and a decrease of TRAb serum 
level after radioiodine therapy.
Material and methods
Patients and radioiodine therapy
This study was designed as a retrospective chart review 
of patients suffering from Graves’ disease with hyperthy-
roidism who underwent radioiodine therapy. Thirty six 
patients (four male, 32 female; age range 18–67 yrs; Me 
46 yrs; mean age ± SD 43 yrs ± 13.0 yrs) with Graves’ 
disease were enrolled in this study. They were selected 
consecutively by one physician. The diagnosis was estab-
lished on common clinical and laboratory criteria. Initially, 
all patien ts were treated with antithyroid drugs (ATDs) for 
the mean period of 28 ± 30 months (range 3–84 months). 
Despite the initial ATDs therapy, all patients were hyper-
thyroid before radioiodine administration, except one 
who was euthyroid (mean serum TSH 0.11 ± 0.5 mU/l, 
Me 0.005 mU/l; fT4 27.1 ± 22.1 pmol/l, Me 20.5 pmol/l). 
Twelve patients suffered from mild Graves’ orbitopathy. 
The maximal administered single dose of radioiodine 
was 22 mCi. The therapy of 24 patients required repeated 
doses of radioiodine. The mean total dose of radioiodine 
was 46.1 mCi ± 21.7 mCi (range 22–88 mCi, Me 44 mCi). 
For further statistical analysis, all data was collected 
immediately before administration of radioiodine and 
18–36 months thereafter. Final data of patients treated with 
repeated doses of radioiodine was collected 18–36 months 
after the last dose of I131.
Thyroid ultrasonography [12]
The thyroid gland of every patient was examined 
ultrasonographically immediately before the admin-
istration of radioiodine, and 18–36 months thereafter 
using a linear transducer (7.5 MHz). The thyroid gland 
volume was estimated by the same physician using the 
ellipsoid formula: width (mm) × depth (mm) × length 
(mm) × 0.52 = volume (ml). Goitre was diagnosed when 
male thyroid volume exceeded 25 ml and female thyroid 
volume exceeded 18 ml. Percentage reduction of thyroid 
volume was estimated as initial thyroid volume (ml)/
/final thyroid volume (ml) ×100%. 
Laboratory results
Serum TSH and free thyroxine (fT4) were measured using 
the electrochemiluminescence technique in Cobas E 601 
(norm range TSH 0.27–4.2 mU/l; ft4 11.5–21.0 pmol/l). Esti-
mations of TRAb were done via radioimmunoassay TRAK 
Human Brahms (norm < 2 IU/l). Percentage reduction of 
TSH receptor autoantibodies was estimated as initial TRAb 
titre (IU/l)/final TRAb titre (IU/l) × 100%.
Statistical analysis
Statistical analysis was performed with GraphPad 
InStat. The level of significance was indicated by 
p values. All p values of less than 0.05 were considered 
to indicate statistical significance. 
The percentage reduction of thyroid volume under-
went further analysis to refer reliable parameter of thyroid 
volume decrease among the group. Percentage reduction 
of TRAb serum level referred objective parameter of TRAb 
decrease and was also statistically analysed.
Results 
Thyroid volume
Before treatment, mean male (n = 4) thyroid volume 
was 27.9 ml ± 9.6 ml (two males had a goitre), and mean 
female (n = 32) thyroid volume was 20.6 ± 12.7 ml 
(17 females had a goitre). 
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Mean thyroid volume was 2.4 ± 1.7 ml (males) and 
5.3 ± 10.9 ml (females) after therapy. Mean percentage 
of thyroid volume reduction was 83.7% (Table I). Two 
females had a goitre (27 ml and 25 ml).
There was an extremely significant difference 
between mean thyroid volume before radioiodine 
administration and after 18–36 months (Wilcoxon 
matched-pairs signed ranks test, p < 0.0001).
TSH receptor autoantibodies (TRAb)
Before radioiodine administration, mean serum level 
of TSH receptor autoantibodies in the group was 
23 ± 12.3 IU/l (Me 21.7 IU/l, range 3.83–41.3 IU/l). 
Mean serum level of TSH receptor autoantibodies 
after 18–36 months was 9.8 ± 11.5 IU/l (Me 4.5 IU/l, 
range 0.04–40 IU/l). There was an extremely signifi-
cant difference between the mean serum level of TSH 
receptor autoantibodies before and 18–36 months 
after radioiodine therapy (Wilcoxon matched-pairs 
signed ranks test, p < 0.0001). 
Correlation between thyroid volume 
and TSH receptor autoantibodies
Spearman rank correlation test showed an extremely 
significant correlation between thyroid volume and the 
serum level of TRAb (p < 0.0001; r = 0.55).
Correlation between percentage reduction of thy-
roid volume and percentage reduction of serum level 
of TRAb was not statistically significant (Spearman rank 
correlation, p = 0.7; r = 0.07).
Discussion
Volume of thyroid gland as the source of TSH recep-
tors seems to have a strong influence on the level of 
autoantibodies. After 18–36 months of radioiodine 
therapy, final thyroid volume was significantly lower 
than initial thyroid volume. This finding has been 
reported in other researches covering a period of 
one year observation [13, 14]. Radioiodine thyroid 
volume reduction has to be analysed separately from 
surgical methods because of the different pattern of 
TRAb level changing. The decrease of thyroid volume 
is the consequence of damage to the thyroid cells 
and transient elevation of TRAb is described after 
radioiodine administration.
In our study, radioiodine destruction of the thy-
roid tissue was followed by a statistically significant 
decrease of TRAb level. This finding is similar to 
results referred to in other researches with more nu-
merous groups [15]. Laurberg et al. studied 36 patients 
with Graves’ disease treated with I131. Laurberg’s 
investigation showed one-year worsening of TRAb 
titre, which may be explained by the initial thyroid 
tissue damage and release of thyroid antigens. Con-
trary to our findings, TRAb level was above the norm 
range within five years of observation. In our study, 
the observation time was shorter. The crucial differ-
ence between our results may be a consequence of 
the different pattern of radioiodine administration. 
Laurberg’s patients were treated with a single dose of 
radioiodine. Additionally, Laurberg does not report 
the initial thyroid volume of patients with Graves’ 
disease, which, in the case of larger-volume thyroid 
gland, can predict failure in response to a single dose 
of radioiodine [16]. In our study, 24 out of 36 patients 
underwent repeated radioiodine therapy. 
Total radioiodine dose may have a crucial influence 
on the final thyroid volume. If there is a link between 
percentage thyroid reduction and TRAb serum level, the 
dose of I131 may have an impact on therapeutic effect. 
In our study, the decrease of TRAb serum level after 
therapy followed the reduction of thyroid gland vol-
ume. Regalbuto et al. analysed 55 patients with Graves’ 
disease treated with I131. Patients who responded to 
therapy had post-therapy thyroid volume significantly 
lower, and percentage thyroid volume reduction greater, 
than non-responders [13].
We did not find a correlation between percentage 
reduction of thyroid volume and percentage reduction 
of TRAb serum level, but the decreasing tendency of 
these two parameters has been observed. 
Table I. Changes in thyroid volume, TSH receptor antibodies serum level before and after radioiodine therapy
Tabela I. Zmiany objętości tarczycy, stężenia przeciwciał przeciw receptorowi dla TSH przed i po terapii radiojodem
Mean thyroid volume before therapy 
± SD [ml]
Mean thyroid volume after therapy 
± SD [ml]
p Mean percentage reduction 
of thyroid volume [%]
Female Male Female Male < 0.0001 83.7
(n = 32) (n = 4) (n = 32) (n = 4)
27.9 ± 9.6 20.6 ± 12.7 2.4 ± 1.7 5.3 ± 10.9
Mean TRAb level before therapy 
± SD [IU/l]
Mean TRAb level after therapy 
± SD [IU/l]
p Mean percentage reduction 
of TRAb level [%]
23 ± 12.3 9.8 ± 11.5 < 0.0001 49.1
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Massaro et al., in a study of 32 patients with Graves’ 
disease, found significant thyroid volume reduction 
after radioiodine therapy. They did not establish a cor-
relation between percentage reduction of thyroid gland 
volume and functional score (TSH, fT4, fT3 serum level), 
but the period of observation was three to 12 months, 
and this seems to be insufficient [11]. A larger group 
of patients is needed to establish a final answer from 
a statistical analysis.
In our study, a positive correlation between thyroid 
gland volume and level of TRAb has also been found. 
The high level of autoantibodies may be linked to the 
presence of goitre. 
The decrease of the level of TRAb may be in-
complete even after total ablation of thyroid gland. 
Extrathyroid factors, like the bone marrow, may be 
responsible for the secondary autoimmune response 
and may produce autoantibodies after thyroid 
removal. On the other hand, it is reasonable that 
the extrathyroidal tissues are the source of autoan-
tigens. It could be explained also by the fact that 
minimal remnants of thyroid tissue still exist even 
when no thyroid tissue is found. Cigrovski-Berkovic 
et al. described a patient with Graves’ disease who 
underwent total thyroidectomy and persisted mildly 
hyperthyroid with high TRAb postoperative titre. 
Scintigraphy examination found pyramidal lobe and 
remnant thyroid tissue in the left lobe [17]. 
Another study showed that thyroid-stimulating 
hormone-receptor antibodies disappeared within six 
years in all eight patients with Graves’ disease who 
underwent total radioiodine thyroid ablation due to 
coexistent differentiated thyroid carcinoma [12]. 
The percentage of cure with low dose of admin-
istered I131 compared to the percentage of cure with 
higher radiation dose is unsatisfactory [18]. It should 
be further investigated if total thyroid ablation could 
be a new guideline in Graves’ disease therapy. 
Post-therapeutic hypothyroidism and the necessity 
of L-thyroxine replacement are considered as natural 
consequences, rather than side-effects, of radioiodine 
therapy. On the other hand, radioiodine treatment 
of hyperthyroidism may have an influence on the 
increased cancer incidence [19]. Other investigations 
have shown that malignant thyroid lesions after radio-
iodine treatment of benign thyroid diseases are seldom 
detected [20]. Using an advanced dosimetric algorithm 
for activity calculation may help to achieve a balance 
between clinical remission and the risk of radioiodine 
overdose [15]. Further investigations are needed to es-
tablish the role of radioiodine therapy in the treatment 
of Graves’ disease.
Conclusions
1) Radioiodine ablation of thyroid gland is followed by 
a decrease of serum circulating autoantibodies.
2) TRAb concentration is positively correlated with 
thyroid gland volume.
3) Percentage reduction of thyroid tissue is not corre-
lated with the percentage reduction of serum TRAb.
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